Head Of Operational Excellence, Parma Site
Pubblicato il 03-09-2026 - Chiesi USA in Parma
About Us
Chiesi is an international research-focused biopharmaceutical group with 90 years of experience, operating in more than 30 countries, with its headquarters in Parma, Italy. More than 8,000 employees across the group are united by a singular purpose: promoting a healthier world for our people, patients, and the planet. We research, develop, and market innovative drugs across our main therapeutic areas.
At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. This fosters a culture of reliability, transparency, and ethical behaviour at every level. As a Vantaggi Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact.
Diversity and inclusion are at the heart of who we are. We believe our differences make us stronger. We are a vibrant ecosystem of passionate, talented individuals united by strong values, each bringing unique perspectives that help us continuously challenge the status quo for the better.
Chiesi Global Manufacturing Division
Chiesi Group has three production plants:
- Parma (Italy), the strategic hub for the production and distribution of our products, serving as an international supply center with exports to over 80 countries. Solid medicines such as tablets and dry powders for inhalers, solutions and suspensions for inhalations, and sterile suspension vials for endotracheal administration are produced.
- In 2024, a new Biotech Centre of Excellence has launched in Parma, dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins.
- Blois‑La Chaussée Saint Victor plant (France), a center of excellence specializing in the production of Dry Powder Inhalers and Metered Dose Inhalers (MDIs). The site manages direct distribution to customers in the French market and exports to other markets.
- Santana de Parnaiba (Brazil), specialized in the production of pressurized solutions and suspensions for inhalation therapy (pMDIs)